Capricor Therapeutics receives FDA acceptance of BLA for deramiocel
NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...
pharmaphorum4y
NS Pharma takes on Sarepta as FDA approves DMD drug
The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival. NS Pharma ...
pharmaphorum1d
Nippon Shinyaku’s DMD drug fails confirmatory trial
The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the confirmatory RACER53 trial, and was unable to distinguish itself from ...
Zacks Small Cap Research on MSN9d
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease
QNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments ...
Morningstar15d
Nasus Pharma To Present Positive Clinical Results From Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting
TEL AVIV, Israel, Feb. 27, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based ...
Yahoo Finance7d
Solara Active Pharma Sciences Limited (SOLARA.NS)
Solara Active Pharma Sciences Ltd (BOM:541540) reports significant financial growth and strategic advancements despite ongoing challenges. Over the past week, the Indian market has remained flat ...